Pfizer

Pfizer is asking the Food and Drug Administration to expand use of its updated COVID-19 booster shot to children ages 5 to 11.

The patent infringement lawsuits were filed in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany, according to a news release.

Moderna sued Pfizer and its German partner BioNTech on Friday, alleging that the two companies copied Moderna’s technology in developing their COVID-19 vaccine Comirnaty. Moderna said in a news release that Pfizer and BioNTech infringed on patents filed between 2010 and 2016 covering its mRNA technology, which Moderna used to develop its own COVID-19 vaccine, Spikevax.

The findings reflect the changing nature of the pandemic, in which the vast majority of people already have some protection against the virus due to vaccination or prior infection.

Pfizer has asked U.S. regulators to authorize its combination COVID-19 vaccine that adds protection against the newest omicron strains: the BA.4 and BA.5 variants.

Now entering late-stage clinical trials, the vaccine could be approved as soon as 2025.

The Pfizer pill, Paxlovid, is intended for people with COVID-19 who are more likely to become seriously ill. Previously only doctors could prescribe the drug

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection.

The FDA must still decide whether to take the recommendations and approve the COVID-19 vaccine for kids between six months and 5 years old.

COVID-19 shots for U.S. infants, toddlers and preschoolers moved a step closer Wednesday.

The White House has announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S. as it projects COVID-19 infections will continue to spread over the summer travel season. The nation’s first federally backed test-to-treat site is opening Thursday in Rhode Island. The site will provide patients with immediate access to the drug once they test positive....

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries. That includes its top-selling COVID-19 vaccine and treatment. The pharmaceutical giant said early Wednesday that it is launching a program aimed at improving health equity in 45 lower-income countries. Most of those nations are in Africa. The drugmaker aims to provide...

Pfizer says it will seek emergency use authorization for a three-dose course of its COVID-19 vaccine in pediatric patients ages 6 months to 5 years old after publishing data from it’s latest study.

The 18 million kids under 5 are the only group in the U.S. not yet eligible for COVID-19 vaccination.

The center’s director, Dr. Rochelle Walensky, adopted a panel’s recommendation Thursday.

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by late May or early June.

President Joe Biden and his administration want Americans and their doctors to know that the country has an ample supply of the life-saving COVID-19 antiviral treatment Paxlovid and that it no longer needs to be rationed

Pfizer and its partner BioNTech said Thursday new data shows its kid-sized booster shot helps healthy 5- to 11-year-olds rev up virus-fighting antibodies.

Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds

Many Americans can now get a second COVID-19 booster, but it’s hard to tell who really needs another shot right now and who could wait.